Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Recombinant FSH

Follitropin delta

Brand names: Rekovelle

A recombinant human follicle-stimulating hormone (follitropin delta) used for controlled ovarian stimulation in women undergoing assisted reproduction such as IVF/ICSI.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It stimulates ovarian follicular development through FSH receptors on granulosa cells; dosing is individualised using body weight and ovarian reserve markers.

Prescribing in practice

  • Ovarian hyperstimulation syndrome is the main serious risk, so treatment is specialist-supervised with careful monitoring.
  • Dosing is individualised (including by anti-Müllerian hormone and body weight) and the product is not interchangeable unit-for-unit with other follitropins.
  • Multiple pregnancy and thromboembolism risks are increased during stimulation; exclude relevant tumours and untreated endocrine disorders first.

Monitoring

Monitor follicular response with ultrasound (and oestradiol where indicated) to guide management and reduce hyperstimulation risk.

Counselling the patient

  • Dosing is tailored to you and differs from other FSH products, so follow your clinic's instructions exactly.
  • Report abdominal swelling, pain or breathlessness promptly.
  • There is an increased chance of multiple pregnancy.

Evidence & guidelines

Individualised follitropin delta dosing was evaluated against conventional FSH stimulation in the ESTHER randomised trial programme.

Reference: SmPC; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways